

COVID-19 Vaccines - CDC's ACIP Discusses Vaccine Boosters (Day 1)

- On September 22, 2021 the <u>Center for Disease Control and Prevention's (CDC's) Advisory</u>
 <u>Committee on Immunization Practices (ACIP) met</u> for the first of two days of deliberation about booster doses of the mRNA COVID-19 vaccines.
- ACIP recommendations are coordinated with the FDA and at the time of the ACIP meeting, the FDA
 had not issued a decision on authorizing booster doses of Comirnaty. The FDA's Advisory
 Committee had mixed opinions on the booster dose. Last week, they voted against full approval but
 advocated for expanded use under Emergency Use Authorization (EUA) in vulnerable individuals
 including individuals 65 years of age and older.
- Without an FDA approval to consider, the ACIP today briefly reviewed the data supporting booster doses of Comirnaty, data on vaccine effectiveness, and other elements of immunity connected to the pandemic. Key discussion points included:
 - Vaccine-based immunity involves two components, antibody generation and long-term immunity facilitated by memory B and T cells.
 - Older individuals start with lower levels of anti-COVID-19 antibodies and may have less robust memory response for long-term immunity. Thus, older individuals have a higher risk for breakthrough COVID-19 infections.
 - Epidemiological studies indicate reductions in vaccine efficacy in individuals 65 years and older, especially during the recent delta variant surge in July and August.
 - Among adults < 65 years of age, vaccines remain effective in preventing hospitalization and severe disease.
 - Among adults 65 years and older, vaccine effectiveness against infection has declined, with smaller declines observed in the vaccine effectiveness against hospitalizations.
 - No data exists on mixing and matching of Pfizer, Moderna, and Janssen vaccines. The National Institute of Allergy and Infectious Diseases (NIAID) is studying this question, but data is not yet available.
- The ACIP did not make any recommendations.
- Day 2 of the ACIP meeting is scheduled for September 23, 2021 when they will discuss any
 potential FDA actions involving Comirnaty. The OptumRx Pipeline Team plans to attend this meeting
 and will provide an update after that meeting.



optumrx.com

 $OptumRx^{@}\ specializes\ in\ the\ delivery,\ clinical\ management\ and\ affordability\ of\ prescription\ medications\ and\ consumer\ health\ products.$ We are an $Optum^{@}\ company\ --$ a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.